Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
Revenue
Neuren Pharmaceuticals Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$224.3m
|
CAGR 3-Years
311%
|
CAGR 5-Years
257%
|
CAGR 10-Years
52%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$395.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$569.6k
|
CAGR 3-Years
145%
|
CAGR 5-Years
27%
|
CAGR 10-Years
28%
|
|
|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$79.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Syntara Ltd
ASX:SNT
|
Revenue
AU$8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
Neuren Pharmaceuticals Ltd
Glance View
Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.
See Also
What is Neuren Pharmaceuticals Ltd's Revenue?
Revenue
224.3m
AUD
Based on the financial report for Dec 31, 2024, Neuren Pharmaceuticals Ltd's Revenue amounts to 224.3m AUD.
What is Neuren Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 10Y
52%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for Neuren Pharmaceuticals Ltd have been 311% over the past three years , 257% over the past five years , and 52% over the past ten years .
You don't have any saved screeners yet